Rituximab treatment for difficult-to-treat nephrotic syndrome in children: A multicenter, retrospective study

Basit Öğe Kaydı
dc.authorid0000-0002-6026-1064
dc.contributor.authorTaşdemir, Mehmet
dc.contributor.authorCanpolat, Nur
dc.contributor.authorYıldız, Nurdan
dc.contributor.authorÖzçelik, Gül
dc.contributor.authorBenzer, Meryem
dc.contributor.authorSaygılı, Seha Kamil
dc.contributor.authorÖzkayın, Emine Neşe
dc.contributor.authorTürkkan, Özde Nisa
dc.contributor.authorBalat, Ayşe
dc.contributor.authorCandan, Cengiz
dc.contributor.authorÇelakıl, Mehtap
dc.contributor.authorYavuz, Sevgi
dc.contributor.authorAkıncı, Nurver
dc.contributor.authorGöknar, Nilüfer
dc.contributor.authorAkgün, Cihangir
dc.contributor.authorTülpar, Sebahat
dc.contributor.authorAlpay, Harika
dc.contributor.authorSever, Fatma Lale
dc.contributor.authorBilge, İlmay
dc.date.accessioned2021-09-09T09:25:52Z
dc.date.available2021-09-09T09:25:52Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or -resistant) and the dosing regimen. Materials and methods: This multicenter retrospective study enrolled children with difficult-to-treat nephrotic syndrome on rituximab treatment from 13 centers. The patients were classified based on low (single dose of 375 mg/m(2)) or high (2-4 doses of 375 mg/m(2)) initial dose of rituximab and the steroid response. Clinical outcomes were compared. Results: Data from 42 children [20 steroid-sensitive (frequent relapsing / steroid-dependent) and 22 steroid-resistant nephrotic syndrome, aged 1.9-17.3 years] were analyzed. Eleven patients with steroid-sensitive nephrotic syndrome (55%) had a relapse following initial rituximab therapy, with the mean time to first relapse of 8.4 +/- 5.2 months. Complete remission was achieved in 41% and 36% of steroid-resistant patients, with the median remission time of 3.65 months. At Year 2, eight patients in steroid-sensitive group (40%) and four in steroid-resistant group (18%) were drug-free. Total cumulative doses of rituximab were higher in steroid-resistant group (p = 001). Relapse rates and time to first relapse in steroid-sensitive group or remission rates in steroid-resistant group did not differ between the low and high initial dose groups. Conclusion: The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined.
dc.identifier.citationTaşdemir, M., Canpolat, N., Yıldız, N., Özçelik, G., Benzer, M., Saygılı, S. K. ... Bilge, İ. (2021). Rituximab treatment for difficult-to-treat nephrotic syndrome in children: A multicenter, retrospective study. Turkish Journal of Medical Sciences, 51(4), 1781-1790. https://dx.doi.org/10.3906/sag-2012-297
dc.identifier.doi10.3906/sag-2012-297
dc.identifier.endpage1790
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue4
dc.identifier.scopusqualityQ3
dc.identifier.startpage1781
dc.identifier.trdizinid480445
dc.identifier.urihttps://dx.doi.org/10.3906/sag-2012-297
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8066
dc.identifier.volume51
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTÜBİTAK Scientific and Technological Research Council of Turkey
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectFrequently Relapsing Nephrotic Syndrome
dc.subjectImmunosuppressive Agents
dc.subjectSteroid-Dependent Nephrotic Syndrome
dc.subjectSteroid-Resistant Nephrotic Syndrome
dc.subjectRemission
dc.titleRituximab treatment for difficult-to-treat nephrotic syndrome in children: A multicenter, retrospective study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Akgun-Cihangir-2021.pdf
Boyut:
435.67 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu